Pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90075/1/phco.29.7.822.pd

Antipsychotic‐Induced Hyperprolactinemia

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64.pd

Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/106836/1/bdi12160.pd

Precision Pharmacotherapy Enables Precision Medicine

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138280/1/phar1998_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138280/2/phar1998.pd

The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/115979/1/phar1640.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/115979/2/phar1640_am.pd

Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90038/1/phco.31.8.806.pd

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19 genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

Implementing and evaluating virtual patient cases within a team‐based learning pedagogy in a therapeutics course sequence

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149331/1/jac51053.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149331/2/jac51053_am.pd

An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder

BackgroundSecond generation antipsychotic (SGA) use in bipolar disorder is common and has proven effective in short‐term trials. There continues to be a lack of understanding of the mechanisms underlying many of their positive and negative effects in bipolar disorder. This study aimed to describe the metabolite profiles of bipolar subjects treated with SGAs by comparing to metabolite profiles of bipolar subjects treated with lithium, and schizophrenia subjects treated with SGAs.MethodsCross‐sectional, fasting untargeted serum metabolomic profiling was conducted in 82 subjects diagnosed with bipolar I disorder (n = 30 on SGAs and n = 32 on lithium) or schizophrenia (n = 20). Metabolomic profiles of bipolar subjects treated with SGAs were compared to bipolar subjects treated with lithium and schizophrenia subjects treated with SGAs using multivariate methods.ResultsPartial lease square discriminant analysis (PLS‐DA) plots showed separation between bipolar subjects treated with SGAs, bipolar subjects treated with lithium, or schizophrenia subjects treated with SGAs. Top influential metabolite features were associated with several pathways including that of polyunsaturated fatty acids, pyruvate, glucose, and branched chain amino acids.ConclusionsThe findings from this study require further validation in pre‐ and posttreated bipolar and schizophrenia subjects, but suggest that the pharmacometabolome may be diagnosis specific.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/115928/1/cts12324.pd

Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138379/1/phar1968_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138379/2/phar1968.pd